康方生物(9926.HK)首日上市高開45.24% 市值逼近180億港元
格隆匯4月24日丨康方生物(9926.HK)今日首日上市,早盤高開45.24%報23.5港元,盤前成交7.36億港元,最新總市值179億港元。該股IPO價格為16.18港元,認購倍數639.2倍。康方生物是一家臨牀階段生物製藥公司,核心產品雙抗AK104處於行業領先位置,是潛在的下一代全球首創PD-1/CTLA-4雙特異性腫瘤免疫治療關鍵藥物,目前已進入II期臨牀實驗階段,預計最早2021年下半年提交新藥申請。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.